Cargando…
Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma
OBJECTIVE: This study was conducted to assess the efficacy and safety of nimotuzumab combined with radiotherapy (RT) in elderly patients with nasopharyngeal carcinoma. MATERIALS AND METHODS: The clinical data of 75 nasopharyngeal carcinoma patients, who were initially treated with nimotuzumab combin...
Autores principales: | Wang, Fangzheng, Jiang, Chuner, Ye, Zhiming, Sun, Quanquan, Liu, Tongxin, Xu, Min, Wu, Peng, Shi, Kaiyuan, Long, Bin, Fu, Zhenfu, Jiang, Yangming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884184/ https://www.ncbi.nlm.nih.gov/pubmed/29425953 http://dx.doi.org/10.1016/j.tranon.2018.01.013 |
Ejemplares similares
-
Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience
por: Wang, Fangzheng, et al.
Publicado: (2017) -
Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis
por: Wang, Fangzheng, et al.
Publicado: (2020) -
Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Wang, Fangzheng, et al.
Publicado: (2017) -
Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
por: Fangzheng, Wang, et al.
Publicado: (2019) -
Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
por: Wang, Fangzheng, et al.
Publicado: (2018)